PARP inhibitors have shown promising antitumor activity in patients with impaired HR repair [7] and have been recently approved by the FDA for treatment of ovarian cancer patients carrying BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA2 and ovarian carcinoma.